ARID1A is altered in 15.65% of malignant esophagogastric neoplasm patients [2].

ARID1A is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ATM is altered in 5.35% of malignant esophagogastric neoplasm patients [2].

ATM is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ATM status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ATR is altered in 2.32% of malignant esophagogastric neoplasm patients [2].

ATR is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ATR status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ATRX is altered in 2.59% of malignant esophagogastric neoplasm patients [2].

ATRX is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ATRX status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BARD1 is altered in 1.5% of malignant esophagogastric neoplasm patients [2].

BARD1 is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BARD1 status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BRCA1 is altered in 2.18% of malignant esophagogastric neoplasm patients [2].

BRCA1 is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BRCA2 is altered in 5.72% of malignant esophagogastric neoplasm patients [2].

BRCA2 is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BRIP1 is altered in 2.08% of malignant esophagogastric neoplasm patients [2].

BRIP1 is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BRIP1 status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

C11orf30 is altered in 0.54% of malignant esophagogastric neoplasm patients [2].

C11orf30 is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains C11orf30 status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CDK12 is altered in 7.53% of malignant esophagogastric neoplasm patients [2].

CDK12 is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CDK12 status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CHEK1 is altered in 0.84% of malignant esophagogastric neoplasm patients [2].

CHEK1 is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CHEK1 status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CHEK2 is altered in 1.63% of malignant esophagogastric neoplasm patients [2].

CHEK2 is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CHEK2 status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ERCC2 is altered in 1.98% of malignant esophagogastric neoplasm patients [2].

ERCC2 is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERCC2 status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ERCC3 is altered in 0.83% of malignant esophagogastric neoplasm patients [2].

ERCC3 is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERCC3 status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ERCC4 is altered in 2.31% of malignant esophagogastric neoplasm patients [2].

ERCC4 is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERCC4 status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ERCC5 is altered in 1.71% of malignant esophagogastric neoplasm patients [2].

ERCC5 is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERCC5 status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ERCC6 is altered in 1.23% of malignant esophagogastric neoplasm patients [2].

ERCC6 is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERCC6 status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCA is altered in 3.23% of malignant esophagogastric neoplasm patients [2].

FANCA is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FANCA status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCB is altered in 1.43% of malignant esophagogastric neoplasm patients [2].

FANCB is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FANCB status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCC is altered in 1.13% of malignant esophagogastric neoplasm patients [2].

FANCC is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FANCC status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCD2 is altered in 3.08% of malignant esophagogastric neoplasm patients [2].

FANCD2 is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FANCD2 status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCE is altered in 1.57% of malignant esophagogastric neoplasm patients [2].

FANCE is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FANCE status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCF is altered in 0.98% of malignant esophagogastric neoplasm patients [2].

FANCF is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FANCF status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCG is altered in 1.36% of malignant esophagogastric neoplasm patients [2].

FANCG is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FANCG status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCI is altered in 1.89% of malignant esophagogastric neoplasm patients [2].

FANCI is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FANCI status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCL is altered in 1.75% of malignant esophagogastric neoplasm patients [2].

FANCL is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FANCL status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCM is altered in 4.99% of malignant esophagogastric neoplasm patients [2].

FANCM is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FANCM status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

HDAC1 is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains HDAC1 status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

HDAC2 is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains HDAC2 status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

KRAS is altered in 13.4% of malignant esophagogastric neoplasm patients [2].

KRAS is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 0 are open and 1 is closed. Of the trial that contains KRAS status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 2 (0 open) [3].

MCPH1 is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MCPH1 status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MDM2 is altered in 4.44% of malignant esophagogastric neoplasm patients [2].

MDM2 is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MDM2 status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MDM4 is altered in 0.52% of malignant esophagogastric neoplasm patients [2].

MDM4 is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MLF1 is altered in 0.45% of malignant esophagogastric neoplasm patients [2].

MLF1 is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MLF1 status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MLH1 is altered in 1.41% of malignant esophagogastric neoplasm patients [2].

MLH1 is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MLH1 status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MLH3 is altered in 1.22% of malignant esophagogastric neoplasm patients [2].

MLH3 is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MLH3 status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MRE11A is altered in 1.4% of malignant esophagogastric neoplasm patients [2].

MRE11A is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MRE11A status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MSH2 is altered in 2.19% of malignant esophagogastric neoplasm patients [2].

MSH2 is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MSH2 status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MSH3 is altered in 3.65% of malignant esophagogastric neoplasm patients [2].

MSH3 is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MSH6 is altered in 2.61% of malignant esophagogastric neoplasm patients [2].

MSH6 is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MUTYH is altered in 0.81% of malignant esophagogastric neoplasm patients [2].

MUTYH is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MUTYH status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NBN is altered in 1.77% of malignant esophagogastric neoplasm patients [2].

NBN is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains NBN status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NPM1 is altered in 0.41% of malignant esophagogastric neoplasm patients [2].

NPM1 is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PALB2 is altered in 1.83% of malignant esophagogastric neoplasm patients [2].

PALB2 is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PALB2 status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PARP1 is altered in 1.21% of malignant esophagogastric neoplasm patients [2].

PARP1 is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PARP1 status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PARP2 is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PARP2 status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PMS1 is altered in 1.81% of malignant esophagogastric neoplasm patients [2].

PMS1 is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PMS1 status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PMS2 is altered in 2.19% of malignant esophagogastric neoplasm patients [2].

PMS2 is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PMS2 status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

POLE is altered in 3.37% of malignant esophagogastric neoplasm patients [2].

POLE is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains POLE status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PPP2R1A is altered in 1.34% of malignant esophagogastric neoplasm patients [2].

PPP2R1A is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PPP2R1A status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PPP2R2A is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PPP2R2A status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PTEN is altered in 3.29% of malignant esophagogastric neoplasm patients [2].

PTEN is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RAD50 is altered in 1.67% of malignant esophagogastric neoplasm patients [2].

RAD50 is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RAD51 is altered in 0.52% of malignant esophagogastric neoplasm patients [2].

RAD51 is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RAD51 status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RAD51B is altered in 0.17% of malignant esophagogastric neoplasm patients [2].

RAD51B is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RAD51C is altered in 0.97% of malignant esophagogastric neoplasm patients [2].

RAD51C is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RAD51C status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RAD51D is altered in 0.55% of malignant esophagogastric neoplasm patients [2].

RAD51D is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RAD54L is altered in 0.44% of malignant esophagogastric neoplasm patients [2].

RAD54L is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RAD54L status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

SLX4 is altered in 3.43% of malignant esophagogastric neoplasm patients [2].

SLX4 is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains SLX4 status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

SMARCB1 is altered in 0.79% of malignant esophagogastric neoplasm patients [2].

SMARCB1 is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

STAG2 is altered in 0.94% of malignant esophagogastric neoplasm patients [2].

STAG2 is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains STAG2 status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

STK11 is altered in 2.25% of malignant esophagogastric neoplasm patients [2].

STK11 is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains STK11 status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TP53 is altered in 68.57% of malignant esophagogastric neoplasm patients [2].

TP53 is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 2 (0 open) [3].

XRCC1 is altered in 0.48% of malignant esophagogastric neoplasm patients [2].

XRCC1 is an inclusion eligibility criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains XRCC1 status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].